Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study.
Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619886022.
View in:
PubMed
subject areas
Administration, Oral
Administration, Oral
Aged
Aged
Anticoagulants
Anticoagulants
Double-Blind Method
Double-Blind Method
Factor Xa Inhibitors
Factor Xa Inhibitors
Female
Female
Humans
Humans
Middle Aged
Middle Aged
Risk Factors
Risk Factors
Rivaroxaban
Rivaroxaban
Venous Thromboembolism
Venous Thromboembolism
authors with profiles
Gary E Raskob